FDA Turns Down Invivyd's Expansion Request for COVID-19 Antibody
Recently, Invivyd, Inc. found itself facing a significant setback as the FDA denied its request to broaden the emergency use authorization (EUA) for the preventive treatment against COVID-19, specifically for its drug Pemgarda (pemivibart). This denial particularly affects adults and adolescents who experience moderate to severe immune compromise, leaving the existing EUA in place for certain immunocompromised patients.
Ongoing Treatment Options Remain Available
Despite the FDA's decision, the current emergency use of Pemgarda is still valid for specified groups of immunocompromised individuals. Invivyd has indicated that the recent developments concerning the COVID-19 treatment opportunity for pemivibart were not anticipated in their previous financial guidance, signaling potential adjustments in their strategic planning moving forward.
FDA's Reasoning Behind the Rejection
The FDA's refusal seemed grounded in its belief that the analyses for treatment immunobridging concerning a monoclonal antibody (mAb) must showcase superior antiviral activity, rather than just equivalent activity compared to previously authorized COVID-19 mAbs. This rigorous standard implies that unless Invivyd can demonstrate the benefits of pemivibart clearly outweigh its known risks, gaining authorization for an expanded use will remain challenging.
Future Plans for Invivyd
In response to this development, Invivyd intends to provide in-depth data and regulatory correspondence regarding pemivibart, along with VYD2311, to the relevant regulatory bodies. This planned communication will likely address the ongoing trials and anticipated results.
Recent Results from Clinical Trials
Earlier disclosures from Invivyd highlighted promising data from the ongoing Phase 1/2 trial for VYD2311, noting that as of Day 65, the serum concentrations of this drug remain elevated. This substantial level could indicate a significantly longer half-life for VYD2311 compared to its counterpart, pemivibart, which is already authorized for pre-exposure prophylaxis against COVID-19.
Market Reaction and Stock Performance
In the wake of the FDA's announcement, IVVD stock experienced a notable drop, falling by 29.9% to reach $1.24 during premarket trading. Investors appear to be reacting to the implications of this rejection, which casts uncertainty over Invivyd's immediate future in the market.
Insights into Invivyd's Strategic Direction
Going forward, it is essential for Invivyd to reassess its portfolio regarding COVID-19 treatments and possibly refine its clinical approach. Stakeholders will be eagerly awaiting updates that may clarify how the company intends to maneuver through these regulatory hurdles and enhance its product offerings.
Frequently Asked Questions
What did the FDA deny Invivyd?
The FDA denied Invivyd's request to expand emergency use authorization for its COVID-19 antibody treatment, Pemgarda, for specific patient groups.
What is Pemgarda used for?
Pemgarda (pemivibart) is used for pre-exposure prophylaxis against COVID-19 in certain immunocompromised adults and adolescents.
How did the stock market react to the news?
IVVD stock dropped by 29.9% to $1.24 in premarket trading following the FDA's decision.
What are Invivyd's next steps?
Invivyd plans to share more detailed data about Pemgarda and explore the ongoing trials of another treatment, VYD2311.
What does this mean for patients?
The rejection affects the availability of expanded treatment options for some immunocompromised patients but does not eliminate existing treatment protocols.
